Chris Meyer

ABLi is advancing the first disease modifying therapy that works inside and outside of the brain and looks forward to sharing more updates from the BASE-PD study, the first to implement alpha-synuclein PET imaging in the brain as an outcome measurement for success.

At the Needham & Company Conference, CEO Milton Werner shared new data from our completed 201 trial in #ParkinsonsDisease showing that #risvodetinib can reverse the biochemical disease course in PD in just 12 weeks & impacts both #neurodegeneration & #neuroinflammation pathways.

⏩ Watch the full presentation of our new results here: d1io3yog0oux5.cloudfront.net/_51206d3f86ed5…

Hear it straight from our CEO Milton Werner on our groundbreaking approach: 📍 Needham Conference — April 13-16: needhamco.com/conferences/26… 📍 World Parkinson's Congress — May 24-27: wpc2026.org ⚡ Meet the team to hear what motivates our work & follow along for updates.

ABLi’s #biomarker research has mapped both underlying pathways that drive #ParkinsonsDisease - neuroinflammation and neurodegeneration. #risvodetinib targets both pathways directly. Not just symptoms but the disease itself. That's what a disease-modifying therapy looks like.

Today on #WorldParkinsonsDay we are highlighting #TheSpark behind our mission. DYK that Parkinson's disease has no approved therapy that slows or stops progression? For 200 years of research, that hasn't changed. We think it's about to. 🧵

At the @CitizensBank Life Sciences Conference, our CEO Milton Werner, PhD, explains why targeting just one pathway isn’t enough and how #risvodetinib is designed to address both neuronal cell death & neuroinflammation in #ParkinsonsDisease. 🎥 Watch here: bit.ly/4bW7GPc

🧠 At #ADPD2026, CEO Milton Werner, PhD, shared our groundbreaking progress advancing #risvodetinib for #ParkinsonsDisease including new biomarker data that proves risvodetinib is truly modifying human #ParkinsonsDisease. Stay updated: bit.ly/44hcvyf

I encourage you to take a few minutes to watch this video from @MichaelJFoxOrg on why disease-modifying therapies matter and why so many people living with Parkinson’s are still waiting for options that can meaningfully slow progression. It’s a powerful reminder that even an incremental slowing of disease could preserve daily function and the moments that bring joy for patients and families alike. Grateful to the patients, care partners, clinicians, researchers, and advocates driving this forward. At @ABLi_Thera , we’re working every day with urgency and care to advance real disease modification. michaeljfox.org/disease-modify…

We are excited to announce that ABLi has completed a collaboration agreement with The Michael J. Fox Foundation to include #risvodetinib in the Path to Prevention (P2P) Trial. Read the press release to learn more: ablitherapeutics.com/news/detail/96…

A new imaging-drug collaboration aims to show whether progression of Parkinson’s disease can be slowed, not just managed. longevity.technology/news/new-way-t… #longevity #parkinsons #neurotech #digitalhealth #biomarkers #realtimedata #medtech #neurology

#ICYMI last week we announced a collaboration to implement alpha-synuclein PET imaging into our upcoming clinical trials evaluating #risvodetinib as a disease modifying therapy for #ParkinsonsDisease. Read this #ParkinsonsNewsToday article to learn more: bit.ly/45vh6O3

Today we are excited to announce a new strategic collaboration with SynuSight Biotech and XingImaging to evaluate alpha-synuclein clearance from the brain in response to #risvodetinib treatment in #ParkinsonsDisease. Read the press release to learn more: bit.ly/49lRkg9

ABLi Therapeutics is headed to San Francisco for the annual @jpmorgan Healthcare Conference. Our CEO, Milton Werner, will share our progress advancing #risvodetinib for treating Parkinson’s disease and what’s next in 2026. Want to learn more? Reach out: bit.ly/4oXvEwx

Abelson Tyrosine Kinase dysfunction plays a critical role in neurodegeneration pathways. At ABLi, we are engineering selective inhibitors to treat Parkinson’s disease & related diseases with the potential to intervene where disease begins. Learn more: bit.ly/44hcvyf

Risvodetinib is ABLi’s lead selective c-Abl kinase inhibitor designed for once-daily oral use that targets the biological mechanisms driving Parkinson’s disease initiation & progression, rather than just treating the symptoms themselves. Learn more here: bit.ly/3MtzSyE

As we kick off the year, our CEO Milton Werner, reflects on ABLi’s mission: to develop oral Abl kinase inhibitors that intervene where #neurodegenerative disease begins, not just treat symptoms. Watch the full video & visit our website to learn more: bit.ly/3YSQx1f

@gamestop you guys are scammers. Your store labeled The Show 25 for a price of 49.99 but charged me 69.99 claiming that the internet price is the real price. Last time I checked it’s the sticker price that matters. The employee said he would get fired if he helped me #Scam

ABLi Therapeutics Launches with a Focus on Developing Treatments for Neurodegenerative Diseases that Arise from Activation of c-Abl Kinases bit.ly/3H3qyOY

@HelenGuo_ I would also like to listen. Very interesting!

I just interviewed a guy who left consulting to buy a $1.2M ice cream shop. Last month alone, he grew it by 25%. This is his story: